Additionally, in a study of 788 node-negative patients (which showed that TXNIP expression is associated with better prognosis [HR 0.642; p < 0.001]), oncogenic activation of HER2 is associated with decreased TXNIP expression and a concomitant increase in reactive oxygen species (ROS) production in breast cancer [51]. Here, TXNIP is linked to breast carcinoma.